Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is an open-label, randomized, multi-centre study where hospitalized subjects will be randomized in a 2:1 ratio to receive Isoquercetin (IQC-950AN) in addition to standard of care or standard of care only for 28 days following confirmation of a COVID-19 infection.
Description: Disease progression is defined as WHO Clinical Progression Scale ≥6, at any time between Day 1 and Day 28
Measure: Disease Progression Time: 28 daysDescription: Viral load of SARS-CoV-2 RNA (# of viral copies) assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Measure: Changes in viral load from baseline to end of treatment - Mean viral load Time: 28 daysDescription: Viral load of SARS-CoV-2 RNA (# of viral copies) assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Measure: Changes in viral load from baseline to end of treatment - Area under the viral load vs. time profiles Time: 28 daysDescription: Viral load of SARS-CoV-2 RNA (# of viral copies) assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Measure: Changes in viral load from baseline to end of treatment - Time profile of viral load Time: 28 daysDescription: Defined as below the level of quantitation of the assay (qRT-PCR). Viral load of SARS-CoV-2 RNA (# of viral copies) assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Measure: Changes in viral load from baseline to end of treatment - Percentage of patients that are viral negative Time: 28 daysDescription: Disease recovery is defined as WHO Clinical Progression Scale score of ≤2
Measure: Disease Recovery Time: 28 daysDescription: Change in score from baseline to day 28
Measure: Change in WHO Clinical Progression Scale score Time: 28 daysDescription: All-cause mortality calculated at Day 30
Measure: Incidence of all-cause mortality Time: 30 daysDescription: If the patient required supplementary oxygen during hospitalization
Measure: Progression to supplementary oxygen requirement Time: 14 daysDescription: If the patient required mechanical ventilation during hospitalization
Measure: Incidence of mechanical ventilation Time: 14 daysDescription: If the patient was admitted to ICU
Measure: Incidence of ICU admission Time: 14 daysDescription: Length of time in hospital prior to being discharged
Measure: Time to hospital discharge Time: 29 daysDescription: Changes in serum CRP levels
Measure: Changes in serum C reactive protein levels (CRP) Time: 29 daysDescription: Changes in D-dimer levels
Measure: Changes in D-dimer levels Time: 29 daysDescription: Changes in sLDLR expression, and PCSK9 and sACE2 levels
Measure: Changes in soluble low-density lipoprotein receptor (sLDLR) expression and proprotein convertase subtilisin/kexin type 9 (PCSK9) and soluble angiotensin converting enzyme 2 (sACE2) levels Time: 29 daysDescription: Changes in LDL-cholesterol
Measure: Changes in LDL-cholesterol Time: 29 daysDescription: Changes in creatinine
Measure: Changes in creatinine Time: 29 daysDescription: Changes in liver enzymes
Measure: Changes in liver enzymes Time: 29 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports